65,437 trials
Metastatic Breast Cancer · Breast Cancer · Progressive Breast Cancer
Primary: Central Nervous System (CNS) Objective Response Rate — 63 percentage of participants
Non-Hodgkin's Lymphoma
Primary: Independently Assessed Progression-free Survival (PFS) — 4.3; 4.5 Months
Alzheimer's Disease
Primary: Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Apolipoprotein epsilon4 (APOE e4) Negative Cohort — 1.6; -0.2; 0.6; 0.9…
Chronic Rhinosinusitis · Nasal Polyps
Primary: Objective (a) the Effect on Polypoid Mucosal Thickening in the Anterior Ethmoid and Maxillary Sinuses as Measured on Sinus CT Scan. — -8.9; 4.2 % Change
Metastatic Renal Cell Carcinoma
Primary: Objective Response in ISM Good Risk Group — .23 proportion of participants — p=0.042
Human Immunodeficiency Virus
Primary: Prevalence of Adverse Events (Weeks 0-144), Per Event — 13.8; 19.3; 1.0; 4.4 percentage of adverse events
Hemophilia A
Primary: Cumulative Packed Red Blood Cell (PRBC) Volume in the Drainage Fluid During the First 24 Hours Following Surgery in Subjects Receiving ADVATE (rAHF-PFM) by Bolus (BI) or…
Lung Cancer
Primary: Pathologically Complete Response — 0 percentage of participants
Arthroplasty, Replacement, Knee
Primary: Knee Society Score (KSS) Change From Preoperative Time Point to 2 Years — 39.81; 83.97; 41.43; 72.90 units on a scale
Ventilator Associated Pneumonia · Critically Ill
Primary: Endotracheal Tube Colonization — 0.9; 1.6 Log colony form unit (CFU)/ mL
Immunodeficiency Syndrome · Non-Cancer Diagnosis
Primary: Number of Patients Who Achieve Greater Than 50% Donor T-cell Chimerism — 13 Participants
Trichotillomania · Hair Pulling
Primary: The National Institute of Mental Health Trichotillomania Symptom Severity Scale (NIMH-TSS) — 8.4; 8.4 units on a scale
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Chronic GVHD Requiring Systemic Immunosuppressive Treatment — 16 percent of patients
Soft Tissue Sarcoma · Fibrous Histiocytoma · Liposarcoma
Primary: Objective Response Rate for Neoadjuvant Bevacizumab Combined With Radiation Therapy for Intermediate and High-risk Soft Tissue Sarcomas. — 2; 4; 3 participants
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: PFS-6 — 1; 8 Participants